```text
Wiki Article
Abciximab (C7E3, 143653-53-6): A Research Reagent Overview
Abciximab, also identified as C7E3 or bearing the CAS number 143653-53-6, is a a valuable research reagent extensively utilized in platelet research . This antibody fragment selectively targets the glycoprotein IIb/IIIa complex on thrombocytes , preventing clot formation . As a result, it's commonly applied as a method to analyze the mechanisms underlying thrombosis and to evaluate the performance of antiplatelet drugs . Distribution is typically limited to academic settings.
```
The Abciximab Compound Research: Utilizing C7E3 and The 143653-53-6 Substance in Research Investigations
Ongoing research into abciximab, a antiplatelet agent, frequently utilizes the monoclonal antibody C7E3 and the substance identified as 143653-53-6. These materials are essential for examining abciximab's biological activity, determining its efficacy in experimental conditions, and elucidating potential biomarkers of patient outcome. Further investigation leveraging these particular reagents is expected to generate valuable insights for enhancing therapeutic strategies related to cardiovascular disease.
```text
C7E3 abciximab, also known as c7e3fragment, is a GPIIb/IIIa receptor antagonist widely utilized in scientific research. Its primary application lies in platelet aggregation studies, allowing investigators to probe the mechanisms underlying thrombosis and hemostasis. Researchers employ this agent Abciximab research grade to investigate the role of platelet activation in various disease models, including ischemia-reperfusion injury and inflammation. Beyond basic research, abciximab is increasingly used in developing novel antithrombotic therapies and evaluating their efficacy. Furthermore, studies exploring its potential to modulate vascular smooth muscle cell function and reduce intracranial bleeding are ongoing. The availability of c7e3 abciximab facilitates a deeper understanding of platelet-mediated processes and contributes to the advancement of translational medicine. }
```
```text
Exploring Research Possibilities with the Drug Abciximab 143653-53-6 and C7E3
Recent research indicate that this antiplatelet agent (identified as 143653-53-6) offers significant scientific promise, particularly when combined with C7E3. Preliminary observations suggested that this association may boost clinical results in multiple arterial settings. Further examination is centered on understanding the exact mode of action between Abciximab and C7E3, including analysis of platelet cohesion and arterial protection.
- Ongoing study work intend to optimize dosing protocols.
- Laboratory systems are being utilized to more assess the theories.
- Human assessments are required to completely assess clinical efficacy.
```
Abciximab (C7E3) for Research: Specifications and Characteristics (143653-53-6)
Researchers needing C7E3 for in vitro investigations should rigorously evaluate integrity and defined parameters . This product is typically offered as a lyophilized powder and comprehensive analytical data including identity by LC-MS, potency assays, and endotoxin testing must be available. Ensure the supplier's CoA outlines acceptable values for related substances and conforms to all quality assurance criteria .
Pharmaceutical-Grade Abciximab Details & Supply
Acquiring analytical-grade Abciximab, specifically referencing the compound C7E3 and identified by the chemical number 143653-53-6, requires thorough consideration of its source . This antibody is commonly utilized in laboratory investigations , particularly those related to platelet adhesion and occlusion. Existing suppliers offer this reagent in varying quantities , typically ranging from mg to substantial commercial supplies. We advise reviewing the report of quality to verify purity and appropriateness for your specific use . Additionally , check the shelf life date before obtaining to maintain optimal efficacy .
- Standard Purity: >95%
- Keeping Conditions: -20°C in controlled conditions
- Use : Platelet Aggregation Suppression Studies